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Abstract
Background: The role of micronutrient status for the incidence and clinical course of cutaneous leishmaniasis
is not much studied. Still zinc supplementation in leishmaniasis has shown some effect on the clinical
recovery, but the evidence in humans is limited.
Objective: To compare biochemical nutritional status in cutaneous leishmaniasis patients with that in controls
and to study the effects of zinc supplementation for 60 days.
Design: Twenty-nine patients with cutaneous leishmaniasis were treated with antimony for 20 days. Fourteen
of them got 45 mg zinc daily and 15 of them got placebo. Biomarkers of nutritional and inflammatory status
and changes in size and characteristics of skin lesions were measured.
Results: The level of transferrin receptor was higher in patients than in controls but otherwise no differences
in nutritional status were found between patients and controls. No significant effects of zinc supplementa-
tion on the clinical recovery were observed as assessed by lesion area reduction and characteristics or on
biochemical parameters.
Conclusions: It is concluded that nutritional status was essentially unaffected in cutaneous leishmaniasis
and that oral zinc supplementation administered together with intramuscular injection of antimony had no
additional clinical benefit.
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C
utaneous leishmaniasis is caused by different
species of the genus Leishmania, and the esti-
mated number of new cases annually is around
1.1 million (1, 2). In Latin America with the exception
of Chile and Antilles, 638,702 cases were reported in the
period 20012011 (3). Cutaneous leishmaniasis results
from multiplication of Leishmania in the phagocytes
of the skin (4). In Bolivia, most cases are caused by
Leishmania (Viannia) braziliensis (5, 6). The cases are
characterized by one or more lesions with raised borders
often associated with secondary bacterial infection and
frequently localized in the exposed areas of the skin
(79).
Among malnutrition conditions, micronutrient defi-
ciencies can contribute to the exacerbation and delayed
recovery of infectious and chronic non-infectious diseases
(10, 11). In human cutaneous leishmaniasis, a significant
decrease of zinc concentration and increase of copper
concentration in plasma have been demonstrated which
may be associated with the inability of the host to kill
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cess (12, 13). Other aspects of the biochemical nutritional
status in leishmaniasis have not been studied previously.
In Bolivia, no data regarding the prevalence of micro-
nutrient deficiencies in the general population is available.
Regarding therapy for cutaneous leishmaniasis, the sys-
temic use of antimony compounds gives a cure rate of
7790% (1). The results of oral zinc treatment studies
in cutaneous leishmaniasis have been contradictory. A
decrease of erythemas and size of the induration was
reported (14, 15) but others found no effect of zinc on
cutaneous leishmaniasis (16). Still the available data on
the effects of zinc as nutritional supplementation in this
disease are scant.
In the present study, we compared biochemical nu-
tritional status in cutaneous leishmaniasis patients and
matched controls and conducted a placebo-controlled
study on the effect of zinc supplementation in patients
with cutaneous leishmaniasis.
Methods
Patients
The patientswere residents of the IsiboroSe ´cure national
park, a tropical forest of Cochabamba province. The
patientswereselectedonthebasis ofthefollowing criteria:
age 1550 years, diagnosis of cutaneous leishmaniasis
by any of the two laboratory tests described below, and
no history of previous leishmaniasis episodes. Exclusion
criteria were mucosal or mucocutaneous leishmaniasis,
presence of more than two cutaneous lesions, pregnancy,
lactation, use of nutritional supplements, presence of dia-
betes mellitus, chronic renal failure, or liver disease. We
contacted 87 patients with cutaneous leishmaniasis visit-
ing Villa Tunari Hospital and the 34 patients meeting
the inclusion criteriawere selected. All patients completed
a health questionnaire prior to entering the study and
signed a consent form for inclusion into the study.
Control subjects
The controlswereage- and gender-matched subjects living
in the same area as the corresponding patients. All con-
trols completed a health questionnaire prior to entering
the study and signed a consent form for inclusion into
the study. Subjects were excluded if they had diabetes
mellitus, had cardiovascular disease, were in pregnancy
or lactation, or received regular medication or nutritional
supplements.
Zinc supplementation and antimony treatment of cutaneous
leishmaniasis
Patients were randomly allocated to receive zinc or
placebo coded capsules for 60 days. Each zinc capsule
contained 315 mg of zinc gluconate (45 mg zinc) and
each placebo capsule contained 315 mg of corn starch
(Farmacia artesanal, Cochabamba, Bolivia). One capsule
perday (zincor placebo)wastakenafter amealcoinciding
with the time of antimony injection during the therapy
period and continued at the same time thereafter. All
patientsreceivedfor20daysdailyintramuscularinjections
of pentavalent antimony (Glucantime†, Sanofi Aventis
Farmace ˆutica Ltda, Sa ˜o Paulo, Brazil), 20 mg Sb/kg/day.
The physicians in the health care centers of Isiboro-Se ´cure
park administered the injection. The compliance was
assessed by daily reporting of given capsule by the
physicians. Control subjects were not given any drugs or
capsules.
Materials and measurements
Venous blood collection tubes of the Vacutainer† system
(cat no 367874 and 368380) were obtained from Becton
Dickinson AB (Stockholm, Sweden). Blood agar No2
(cat no DF 0027-17-0) was obtained from Difco Labora-
tories Inc (Detroit, Michigan, USA). The Panotic fast
staining system (cat no 620529) was obtained from LB
(Laborclin, Sa ˜o Paulo, Brazil) and disposable plastic
calipers for the measurement of lesion dimensions were
obtained in local commerce.
Collection of blood samples
For patients, blood was sampled three times, before the
start of the treatment (T0), after 20 days at the end of
antimony treatment (T1) and after 60 days of supplemen-
tation with zinc or placebo (T2). For controls, blood
was sampled at time zero only. Blood was collected by
venipuncture after 12 h offasting and 30 min of relaxation
between 7 and 8 in the morning into polystyrene test
tubes. They were centrifuged for 10 min at ]2,000 g
and plasma samples were aliquoted and stored at 808C
until analysis.
Microbiological and biochemical analysis
Parasite identification was performed by microscopy of
stained smears of scrapings of lesion borders and by
isolation in culture (17). Briefly, smears of scrapings of
lesion borders in triplicate were stained with the Panotic
fast system and microscopically assessed for amastigote
forms of the parasite. The isolation by culture was
performed by inoculation of aspirates into tubes contain-
ing blood agar base No2 and 10% rabbit defibrinated
blood (18). The tubes were incubated at 268C for 10 days
andthepromastigoteformofparasitewasmicroscopically
assessed. Total number of white blood cells, neutrophils,
eosinophils and lymphocytes (as fraction of white blood
cells), red blood cells, hemoglobin, and hematocrit were
measured within 30 min after blood sampling using the
Auto hematology analyzer BC-3000 Plus, Mindray
TM
(Nanshan, Shenzhen, China) at the Villa Tunari Hospital.
ASAT, ALAT, urea, and glucose in serum were also
measured by photometry. The transferrin receptor was
measured by an ELISA test kit (R&D Systems) at the
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measurements were performed at the Clinical Chemistry
Laboratory of Ska ˚ne University Hospital, Lund, Sweden,
using certified methods. These data were compared with
the reference ranges for healthy subjects established at
that laboratory.
Assessment of lesion healing
The cutaneous lesions were assessed in two time phases,
the first one at 3, 9, 15, and 20 days, concomitant with
antimony treatment and then every 10 days during the
last 40 days. Area of lesion (mm
2) and presence of raised
edge of lesion, inflammatory halo, satellite lesions, and
purulent material were measured. The area was calcu-
lated using the formula for a circle or ellipse based on
measurements with a caliper. The healing of lesions was
expressed as percent reduction of the initial area.
Ethics permission
Ethics permission for procedures involving human vo-
lunteers was obtained from the Bolivian Ethics Com-
mittee of the Medical Faculty, Universidad Mayor de
San Simo ´n and the Regional Ethics Committee, Lund,
Sweden (no. 2009/171).
Statistical analysis
TheSPSSsoftwarewasused.TheMannWhitneytestwas
used for testing the significance of differences between
two non-normally distributed continuous variables for
comparisons between patients and controls and also for
two non-normally distributed quantitative discrete vari-
ables between zinc-supplemented and placebo groups.
Chi-squareanalysiswasused forcomparison ofindividual
characteristics of the lesions between the groups. The
Wilcoxon signed rank test was used to compare the same
variables of patients at T0, T2 and in controls for the two
groups (zinc-supplemented or placebo). No corrections
for multiple testing were made.
Results
Comparison of nutritional status in patients and controls
For patients and 29 matched controls there were no
statistically significant differences in weight, height and
body mass index (BMI) (Supplementary Table 1). The
plasma concentrations of nutrient-related compounds
(Table 1) showed in both patient groups increased values
of transferrin receptor at T0 compared with the corre-
sponding controls (p0.002 and 0.033, respectively). Still
a concentration above the reference range was observed
in only two female patients at T2. This can reflect depleted
iron storage and the two patients had also subnormal
concentrations of iron and ferritin in plasma and high
values of the total iron-binding capacity and also low
blood hemoglobin values both at T0 and T2. A slightly
lower concentration of sodium at T0 in the placebo group
compared to control was observed (p0.05). For plasma
vitamin B12, subnormal values were observed in five
patients at T0 and also at T2 and in three controls but no
significant differences between the group mean values
were observed. For other nutrient-related compounds,
there were no significant differences between patients at
T0 and controls (Table 1).
Clinical observations after zinc supplementation
Thirty-four patientsenteredin thestudyand29completed
it. The reasons for dropping out in the placebo group
were low adherence to the supplementation and clinical
follow-up in three cases and low adherence to the anti-
mony treatment in one case. In the zinc-supplemented
group one case dropped out due to low adherence to the
clinical follow up. The time course for reduction of lesion
area did not differ significantly between placebo and zinc-
supplemented groups (Fig. 1). The differences in lesion
area (%) were significant for the intervals day (915),
(1520), and (2030) in both groups (Table 2). Regarding
the four lesion characteristics, a higher frequency of
purulent material (an indicator of superinfection) and of
inflammatory halo was found in the zinc-supplemented
group at day 20 only (Chi-square test p50.05) (Fig. 2).
Biochemical markers after zinc supplementation
The number of red cells, hematocrit, and the hemoglobin
concentration were decreased at T1 in both zinc-supple-
mented and placebo groups compared to data at T0
(Supplementary Table 2). The total number of leucocytes
was lower in both groups at T0 and the fraction of
lymphocytes was lower at T1 and T2 in the placebo
group comparedwith the data in controls (Supplementary
Table 2). The enzymes ASAT and ALAT tended to be
higher at T1 than at T0 and T2 (Supplementary Table 3).
Thesefindingsmaypartlyindicatesideeffectsofantimony
treatment.
Regarding inflammatory markers (Supplementary
Table 4), an increase of CRP at T2 compared to at T0
was found in the zinc-supplemented group together with
a small decrease in the placebo group although without
statistical significance in both cases. The concentration
of haptoglobin was decreased at T2 compared to T0 in
both zinc-supplemented and placebo groups. Orosomu-
coid was decreased in the placebo group at T2 compared
to T0.
Regarding nutrient-related compounds (Table 1), the
concentration of folate was decreased at T2 compared
to T0 in the zinc-supplemented group. At T2 the cal-
cium concentration in the placebo group was decreased
(p0.012). The comparison of the differences T2T0
between zinc-supplemented and placebo groups showed
a significantly larger decrease of folate and smaller
increase of transferrin receptor in the zinc-supplemented
group compared with the placebo group.
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mentary Table 5), decreased concentration of creatinine
was found at T2 in the zinc-supplemented group com-
pared with T0 (p0.019). Regarding gammaglutamyl-
transferase (GT) only one patient had high values at T0
and T2 and also one control. Alkaline phosphatase (ALP)
was slightly elevated in four patients at T0, nine patients at
T2 and in seven controls. No differences were found
between zinc-supplemented and placebo groups in these
respects.
Discussion
Nutritional status
Regarding general nutritional status in leishmaniasis,
a low BMI (B18.5 kg/m
2) was found in 10% and
hypoalbuminemia (B35 g/L) in 12% of the patients (19).
In our patient group only one patient (of 29) has such
a low BMI and three patients had a BMI below 20 kg/m
2.
Only one of our patients had a plasma albumin below
35 g/L. In another study, children with visceral leishma-
niasis were found to have a lower BMI and plasma
albumin than the other groups studied (20). The loss of
weight may be attributable in cases of American tegu-
mentary leishmaniasis to difficulties to eat (19) and in
visceral leishmaniasis to the cachexia caused by the
infection (20).
Concerning the nutrient-related compounds of plasma,
the concentration of transferrin receptor was higher in
patientsthanincontrols(Table1).Alsolowlevelsofplasma
iron and high levels of iron-binding capacity were ob-
served in several patients. The subnormal iron status can
at least partly be explained by a sequestration of iron
which can limit the leishmania infection (2123). Other
authors also reported decreased levels of iron plasma
concentration in cutaneous and visceral leishmaniasis
which was interpreted partly as a response to the effect
of immunoregulatory cytokines (24, 25).
Table 1. Plasma concentration of nutrient-related compounds in cutaneous leishmaniasis patients before and after zinc supplementation and in
controls
p
Concentration in plasma T0 T2 Control
aT2 vs. T0
aT0 vs. Ctrl
aT2 vs. Ctrl
bT2T0 Zinc vs. Placebo
Zinc group (n14)
Vitamin B12 (pmol/L) 298 (131) 291 (105) 251 (68) 0.92 0.16 0.14 0.43
Folate (nmol/L) 19 (5) 15 (3) 15 (3) 0.004 0.12 0.82 0.023
Cholesterol (mmol/L) 3.6 (0.8) 3.6 (0.7) 3.8 (0.5) 0.83 0.55 0.43 0.79
Triglyceride (mmol/L) 0.9 (0.3) 0.9 (0.6) 1.1 (0.7) 0.47 0.97 0.87 0.36
Calcium (mmol/L) 2.4 (0.1) 2.3 (0.1) 2.3 (0.1) 0.27 0.41 0.10 0.71
Magnesium (mmol/L) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.35 0.42 0.21 0.26
Sodium (mmol/L) 142 (2.5) 140 (4.0) 143 (2.4) 0.10 0.19 0.02 0.56
Potassium (mmol/L) 3.9 (0.5) 4.1 (1.1) 4.5 (1.7) 0.98 0.30 0.68 0.91
Phosphate (mmol/L) 1.6 (0.9) 1.6 (1.1) 1.5 (0.9) 0.93 0.77 0.97 0.33
Iron (mmol/L) 15 (6.3) 15 (7.0) 19 (9.0) 0.58 0.30 0.39 0.76
Ferritin (mg/L) 99 (145) 101 (131) 78 (43) 0.27 0.19 0.47 0.41
Transferrin receptor (nmol/L) 16 (3.4) 18 (17.3) 12 (3.0) 0.15 0.002 0.17 0.019
TIBC (mmol/L) 71 (12) 66 (17) 71 (6) 0.11 0.83 0.22 0.60
Placebo group (n15)
Vitamin B12 (pmol/L) 228 (87) 235 (82) 234 (75) 0.36 0.59 0.87
Folate (nmol/L) 17 (5) 17 (4) 19 (5) 0.82 0.30 0.27
Cholesterol (mmol/L) 4.3 (1.2) 4.3 (1.1) 4.7 (1.2) 0.82 0.17 0.31
Triglyceride (mmol/L) 0.9 (0.3) 1.1 (0.4) 1.3 (0.7) 0.38 0.06 0.48
Calcium (mmol/L) 2.3 (0.1) 2.3 (0.1) 2.4 (0.1) 0.53 0.057 0.012
Magnesium (mmol/L) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.80 0.23 0.19
Sodium (mmol/L) 142 (3.2) 141 (5,1) 144 (3.5) 0.61 0.050 0.01
Potassium (mmol/L) 3.9 (0.7) 4.1 (0.9) 4.7 (1.7) 0.89 0.10 0.19
Phosphate (mmol/L) 1.7 (1.0) 1.3 (0.7) 1.8 (1.1) 0.14 0.86 0.08
Iron (mmol/L) 15 (7.6) 15 (5.9) 18 (7.1) 0.91 0.43 0.31
Ferritin (mg/L) 86 (120) 81 (91) 134 (126) 0.91 0.14 0.09
Transferrin receptor (nmol/L) 15 (5.5) 19 (11.8) 11 (3.1) 0.07 0.033 0.005
TIBC (mmol/L) 71 (11) 68 (11) 71 (7.4) 0.16 0.86 0.28
The data are expressed as mean (SD).
Ctrl, Control. TIBC, total iron-binding capacity.
aWilcoxon’s signed-rank test, level of significance pB0.05;
bMannWhitney test, level of significance pB0.05.
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This study explored the effects of zinc provided as a
nutritional supplement in addition to antimony treatment
on changes in lesions and biochemical markers in patients
with cutaneous leishmaniasis. No additional effect of zinc
on lesion healing was found which can be explained by
the high efficacy of antimony alone. Previously oral zinc
sulfate was studied as an anti-leishmania drug and the
cure rates were 83.9, 93.1 and 96.9% with the doses of 2.5,
5 and 10 mg/kg/day, respectively (14). A comparison of
treatment by zinc sulfate (10 mg/kg/day) and the intra-
muscular antimony treatment (20 mg/kg/day) showed no
difference in cure rates (30.2 and 35.5%, respectively)
(16). The dose of zinc used by us (45 mg/day) is close to
2.5 mg/kg/day of zinc sulfate (assuming that the latter
was given as the heptahydrate). The present study seems
to be the only one in which oral zinc as nutritional
supplementation has been combined with intramuscular
antimony injections. Zinc has also been used as intrale-
sional treatment. Injection of 2% zinc sulfate, 7% sodium
chloride or pentavalent antimony all gave cure rates of
8595% (26). In a similar study of intralesional injections
zinc sulfate gave a cure rate of 83.8% and pentavalent
antimony of 60% (27). Other intralesional treatments
have been proposed (28) and therapy options in general
have been summarized in a Cochrane review (9). There
is a need to further study the effects of intralesional
treatments and of oral supplementation with zinc and
other nutrients.
The many effects of zinc on wound healing in general
have been reviewed (2931). An important effect is ex-
erted by zinc metalloenzymes involved in membrane
stability and in the maturation of collagen during the
proliferative and remodeling phases of wound healing.
Many factors also affect the defense against parasites
and how parasites can escape control. This may be due
to a complex interaction between molecules released
by the parasites to assure survival (32) and the host
immune response through release of oxidant molecules
and increase of the concentration of pro-inflammatory
cytokines (33).
Biochemical markers
In visceral leishmaniasis, other authors found a signi-
ficantly increased level of CRP both before and after
treatment compared to controls but then CRP decreased
to similar levels as in controls at 90 days after treatment
(3436). In our study CRP was above the reference
value 3.0 mg/L in nine patients at T0, nine patients at
T2 and in six controls but the data did not show signi-
ficant changes with time. The indicators of liver func-
tion before and after therapy plus supplementation in
our study did not show significant changes between zinc-
supplemented and placebo groups and also compared
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Fig. 1. Changes of the lesion area in patients with cutaneous
leishmaniasis during the supplementation period with zinc
or placebo.
aBefore starting treatment,
bend of antimony
therapy,
cend of supplementation period. Mann-Whitney
test, p 0.05 at all time points.
Table 2. The changes in lesion area in patients with cutaneous leishmaniasis as measured as differences of area between occasions of clinical
observation in zinc-supplemented and placebo groups
Differences in lesion area (mm
2) p
Differences in days Zinc suppl. (n14) Placebo (n15)
aZinc suppl.
aPlacebo
bZinc vs. Placebo
03 22.5 (143) 0 (49) 0.72 0.50 0.59
39 34 (155) 35 (130) 0.65 0.023 0.62
915 81 (192) 22 (181) 0.017 0.009 0.72
1520 29.5 (93) 9 (106) 0.003 0.012 0.38
2030 6.5 (73) 3 (52) 0.012 0.043 0.51
3040 0 (12.5) 0 0.71 0.18 0.65
4050 0 (44) 0 0.06 0.31 0.56
5060 0 0 1.00 0.18 0.71
Data were expressed as median (IQR).
aWilcoxon’s signed-rank test, level of significance pB0.05,
bMannWhitney test, level of significance pB0.05.
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of ASAT during treatment with antimony (37, 38), but
other trials evaluating the tolerability of antimony and
miltefosine reported no changes in hepatic parameters
(39, 40).
Strengths and weaknesses
This pilot study is the first one on the effects of oral zinc
supplementation combined with intramuscular antimony
therapy. A careful characterization of nutritional status
in leishmaniasis patients was performed and compared
with that in matched controls. Extensive documentation
was made using clinical chemistry measurements and the
study provides a possible model for performing interven-
tion studies in Bolivia. In future studies, a larger number
of patients should be included and additional biomarkers
be used.
Conclusions
Nutritional status in cutaneous leishmaniasis was es-
sentially normal. No additional clinical benefit of zinc
supplementation could be documented probably because
antimony treatment alone had a high efficiency. Several
changes were observed in different biochemical markers
which could be attributed to other factors than a direct
effect of zinc. There is a need to further study different
treatments in leishmaniasis and the possible additive
effects of zinc and other nutrients.
Acknowledgements
The study was part of a collaborative program between Universidad
Mayor de San Simo ´n and Lund University on Health and Nutrition
supported by SIDA (Swedish International Development Agency).
Further support was obtained from the EU project ECNIS2. We
thankthepatientsfortheirparticipation.Wealsothankthepersonnel
at the Villa Tunari Hospital, Dr. Daniel Illanes, Dr. Claudia Lazarte,
Dr. Yvonne Granfeldt, and Prof Leif Bu ¨low for helpful support.
Conflict of interest and funding
The authors declare no conﬂict of interests.
References
1. World Health Organization (2010). Control of leishmaniasis:
report of a meeting of the WHO expert committee on the con-
trol of leishmaniasis. Geneva. http://www.who.int/iris/handle/
10665/44412 [cited 19 January 2013].
2. World Health Organization (2010). Working to overcome the
global impact of neglected tropical diseases. First WHO report
on neglected tropical diseases. http://www.who.int/iris/handle/
10665/44440 [cited 19 January 2013].
3. Pan American Health Organization (2013). Leishmaniasis: 2007
update. http_www.paho.org_leishmaniasis [cited 6 June 2013].
4. Salehizadeh E, Nahrevanian H, Farahmand M, Hajihosseini R,
Saghiri R, Khalili G. In vivo application of killed leishmania
vaccine and imiquimod as adjuvant in Balb/c mice infected
with Leishmania major MHRO/IR/75/ER as Iranian strain. Res
J Parasitol 2011; 8: 11626.
5. Rojas E, Parrado R, Delgado R, Reithinger R, Garcia AL.
Leishmaniasis in Chapare ´, Bolivia. Emerg Infect Dis 2009; 15:
67880.
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
0
20
40
60
80
100
Zinc supplement (n =14)
Placebo (n =15)
Day 0a Day 3 Day 9 Day 15 Day 20b Day 30 Day 40 Day 50
Days of clinical observation
Day 60c
1. lesion raised edge
2. Inflammatory halo
3. Satellite lesion
4. Purulent material
F
r
e
q
u
e
n
c
y
 
o
f
 
l
e
s
i
o
n
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
i
n
 
p
e
r
c
e
n
t
a
g
e
Fig. 2. Clinical characteristics of cutaneous leishmaniasis lesions in zinc or placebo supplemented groups (expressed as percent
of occurrence).
aStarting treatment,
bend of antimony therapy,
cend of supplementation period. Signiﬁcant differences between groups at 20th
day for purulent material and inﬂammatory halo (Chi-square test, p50.05).
Miguel Guzman-Rivero et al.
6
(page number not for citation purpose)
Citation: Food & Nutrition Research 2014, 58: 23353 - http://dx.doi.org/10.3402/fnr.v58.233536. Bermudez H, Rojas E, Garcia L, Desjeux P, Dujardin J-C,
Boelater M, et al. Generic sodium stibogluconate is as safe and
effective as branded meglumine antimoniate, for the treatment
of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Ann Trop Med Parasitol 2006; 100: 591600.
7. Jones TC, Johnson WDJ, Barretto AC, Lago E, Marsden PD.
Epidemiology of American cutaneous leishmaniasis due to
Leishmania braziliensis. J Infect Dis 1987; 156: 7383.
8. Vieira-Gonc ¸alves R, Pirmez C, Jorge ME, Souza WJ, Oliveira
MP, Rutowitsch MS, et al. Clinical features of cutaneous and
disseminated cutaneous leishmaniasis caused by Leishmania
(Viannia) braziliensis in Paraty, Rio de Janeiro. Int J Dermatol
2008; 47: 92632.
9. Gonza ´lez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J,
Tweed JA. Interventions for American cutaneous and mucocu-
taneous leishmaniasis (Review). Cochrane Database Syst Rev
2009; (2): CD004834. doi: 10.1002/14651858.CD004834.pub2.
10. Tulchinsky TH. Micronutrient deﬁciency conditions: Global
health issues. Public Health Rev 2010; 32: 24355.
11. Taylor CE, Higgs ES. Micronutrients and infectious diseases:
thoughts on integration of mechanistic approaches into micro-
nutrient research. J Infect Dis 2000; 182(Suppl 1): S14.
12. Amini M, Nahrevanian H, Khatami S, Farahmand M, Mirkhani
F, Javadian S. Biochemical association between essential trace
elements and susceptibility to Leishmania major in BALB/c and
C57BL/6 mice. Braz J Infect Dis 2009; 13: 835.
13. Van Weyenbergh J, Santana G, D’Oliveira A, Jr, Santos AF, Jr,
Costa CH, Carvalho EM, et al. Zinc/copper imbalance reﬂects
immune dysfunction in human leishmaniasis: an ex vivo and in
vitro study. BMC Infect Dis 2004; 17: 50.
14. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc
sulphate in the treatment of acute cutaneous leishmaniasis. Clin
Exp Dermatol 2001; 26: 216.
15. Prasad AS. Impact of the discovery of human zinc deﬁciency on
health. J Am Coll Nutr 2009; 28: 25765.
16. Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee
M, Famili S, Tavakoli Rodi I, et al. Comparison of oral zinc
sulfate with systemic meglumine antimoniate in the treatment of
cutaneous leishmaniasis. Dermatol Res Pract 2011; 2011: 269515.
17. Torrico-Rojas MC. Manual de normas y procedimientos
te ´cnicos de laboratorio para Leishmaniasis. Ministerio de Salud
y Deportes Bolivia; 2010. La Paz Bolivia. ISBN:978-99954-
50-13-7.
18. Bermu ´dez H, Solano M, Torrico-Rojas MC, Carballo-Montero
M, Lafuente-Covarrubias O, Lara-Arias MP, et al. Diagnostico
de leishmaniasis utilizando medio de cultivo TSTB en pacientes
del tropico de Cochabamba. Gac Med Bol 2005; 28: 315.
19. Oliveira AGL, Brito PD, Schubach AO, Oliveira RV, Saheki
MN, Lyra MR, et al. Inﬂuence of the nutritional status in the
clinical and therapeutical evolution in adults and elderly with
American Tegumentary Leishmaniasis. Acta Trop 2013; 128:
3640.
20. Maciel BL, Lacerda HG, Queiroz JW, Galva ˜o J, Pontes NN,
Dimenstein R, et al. Association of nutritional status with the
response to infection with Leishmania chagasi. Am J Trop Med
Hyg 2008; 79: 5918.
21. Baynes RD. Assessment of iron status. Clin Biochem 1996; 29:
20915.
22. Shaw JG, Friedman JF. Iron deﬁciency anemia: focus in
infectious diseases in lesser developed countries. Anemia 2011;
2011: 260380.
23. Kumar V, Choudhry VP. Iron deﬁciency and infections. Indian J
Pediatr 2010; 77: 78993.
24. Machado-Coelho GL, Caiaffa WT, Genaro O, Magalha ˜es
PA, Mayrink W. Risk factors for mucosal manifestation of
American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg
2005; 99: 5561.
25. Lal CS, Kumar S, Ranjan A, Rabidas VN, Verma N, Pandey K,
et al. Comparative analysis of serum zinc, copper, magnesium
calcium and iron level in acute and chronic patients of visceral
leishmaniasis. J Trace Elem Med Biol 2013; 27: 98102.
26. Sharquie KE, Najim RA, Farjou IB. A comparative controlled
trial of intralesionally-administered zinc sulphate, hypertonic
sodium chloride and pentavalent antimony compound against
acute cutaneous leishmaniasis. Clin Exp Dermatol 1997; 22:
16973.
27. Iraji F, Vali A, Shahtalebi AM, Momeni AZ. Comparison of
intralesionally injected zinc sulphate with meglumine antimoni-
ate in treatment of acute cutaneous leishmaniasis. Dermatology
2004; 209: 469.
28. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado
M, et al. Intralesional antimony for single lesions of Bolivian
cutaneous leishmaniasis. Clin Infect Dis 2013; 56: 125560.
29. Burns JL, Mancoll JS, Phillips LG. Impairments to wound
healing. Clin Plast Surg 2003; 30: 4756.
30. Harris CL, Fraser C. Malnutrition in the institutionalized
elderly: the effect on wound healing. Ostomy Wound Manage
2004; 50: 5463.
31. Guo S, Dipietro LA. Factors affecting wound healing. J Dent
Res 2010; 89: 21929.
32. Zambrano-Villa S, Rosales-Borjas D, Carrero JC, Ortiz-Ortiz L.
How protozoan parasites evade the immune response. Trends
Parasitol 2002; 18: 2728.
33. Bogdan C, Ro ¨llinghoff M. The immune response to Leishma-
nia: mechanisms of parasite control and evasion. Int J Parasitol
1998; 28: 12134.
34. Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and
C-reactive protein levels in Indian Kala azar patients: correla-
tion with clinical outcome. Clin Immunol 2007; 122: 3438.
35. Paltrineri S, Ravicini S, Rossi G, Roura X. Serum concentration
of the derivatives of reactive oxygen metabolites (d-ROMs) in
dogs with leishmaniosis. Vet J 2010; 186: 3935.
36. Wasunna KM, Raynes JG, Were JB, Muigai R, Sherwood J,
Gachihi G, et al. Acute phase protein concentrations predict
parasite clearance rate during therapy for visceral leishmaniasis.
Trans R Soc Trop Med Hyg 1995; 89: 67881.
37. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas
CM, et al. Efﬁcacy and toxicity of sodium stibogluconate for
mucosal leishmaniasis. Ann Intern Med 1990; 113: 93440.
38. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira
RV, Marzochi MC, et al. Systematic review of the adverse effects
of cutaneous leishmaniasis treatment in the New World. Acta
Trop 2011; 118: 8796.
39. Soto J, Valda-Rodriguez L, Toledo J, Vera-Navarro L, Luz M,
Monasterios-Torrico H, et al. Comparison of generic to branded
pentavalent antimony for treatment of new world cutaneous
leishmaniasis. Am J Trop Med Hyg 2004; 71: 57781.
40. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B,
Rahnema A, et al. Comparison of miltefosine and meglumine
antimoniate for the treatment of zoonotic cutaneous leishma-
niasis (ZCL) by a randomized clinical trial in Iran. Acta Trop
2007; 103: 3340.
*Miguel Guzman-Rivero
Biomedical Nutrition, Pure and Applied Biochemistry
Lund University
PO Box 124
SE-22100 Lund, Sweden
Email: Miguel.Guzman@tbiokem.lth.se; miguelguzmanrivero@yahoo.es
Nutritional status and zinc supplementation in leishmaniasis
Citation: Food & Nutrition Research 2014, 58: 23353 - http://dx.doi.org/10.3402/fnr.v58.23353 7
(page number not for citation purpose)